April 2012 in “The Journal of Urology” This study found that among prostate cancer patients undergoing a biopsy, those with metabolic syndrome tended to have a lower Gleason score compared to those without the syndrome.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
3 citations
,
December 2016 in “Canadian Urological Association journal” This study suggests that male pattern baldness—especially moderate to severe—is an independent risk factor for prostate cancer and high-grade disease in men undergoing prostate biopsy.
September 2010 in “European Urology Supplements” PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.